Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine for ultra-early COVID-19 infection vs azvudine (Rongxian People's Hospital)
ChiCTR2300069528Phase 4Suspended
- Sponsor
- Rongxian People's Hospital
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lamivudine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Rongxian People's Hospital. Primary endpoints: Duration of clinical symptoms, Incidence of pneumonia manifestations on pulmonary imaging and 2 more. Started Apr 2023; status: suspended.
02
Drugs
lamivudine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300069528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069528.